Dinutuximab

Monoclonal antibody

Approvedregulatory verdict

Evidence outlook

Approved: Neuroblastoma

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

The registry's posted analysis (3-year EFS 62.9% vs 48.1%, log-rank p=0.1016) differs from the published primary analysis that stopped randomisation for efficacy (2-year EFS 66% vs 46%, P=0.01).

track record: Partial signal

Also approved (1)
CA
  • High-risk neuroblastoma in paediatric patients, with GM-CSF, IL-2 and 13-cis-retinoic acid, after at least a partial response to prior first-line multimodal therapy
Product first approved 2018newswire.ca

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (5)
Neuroblastoma
NCT03126916 · Children's Oncology Group
2018-05-14 – 2030-09-30 · Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, Neuroblastoma
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT03098030 · United Therapeutics
2017-06-01 – 2020-03-26 · Small Cell Lung Cancer
What this study did
Phase 2 (11)
Neuroblastoma
NCT07932808 · Giselle Sholler
2026-11-26 – 2040-11-26 · Neuroblastoma
What this study did
NCT06450041 · New Approaches to Neuroblastoma Therapy Consortium
2024-12-16 – 2038-12 · Neuroblastoma
What this study did
NCT07261241 · New Approaches to Neuroblastoma Therapy Consortium
2026-12-31 – 2031-12-31 · Neuroblastoma
What this study did
NCT05421897 · Children's Hospital Los Angeles
2022-11-29 – 2029-11 · Neuroblastoma
What this study did
NCT03794349 · Children's Oncology Group
2019-07-08 – 2029-03-31 · High Risk Neuroblastoma, Recurrent Neuroblastoma, Refractory Neuroblastoma
What this study did
NCT04385277 · Children's Oncology Group
2020-12-31 – 2027-09-30 · Ganglioneuroblastoma, Nodular, Neuroblastoma
What this study did
NCT03786783 · National Cancer Institute (NCI)
2019-03-04 – 2026-03-31 · Ganglioneuroblastoma, High Risk Neuroblastoma
What this study did
NCT01767194 · National Cancer Institute (NCI)
2013-02-12 – 2022-09-30 · Ganglioneuroblastoma, Recurrent Neuroblastoma
What this study did
NCT02169609 · Fundació Sant Joan de Déu
2014-11-26 – 2018-12-31 · Neuroblastoma, Neoplasm, Residual, Effects of Immunotherapy
What this study did
NCT02641782 · University of Cologne
2015-11 – 2017-01-30 · Neuroblastoma
What this study did
Other / comorbidity
NCT02484443 · National Cancer Institute (NCI)
2016-02-04 – 2023-09-30 · Metastatic Malignant Neoplasm in the Lung, Metastatic Osteosarcoma, Recurrent Osteosarcoma
What this study did
Phase 1/2 (4)
Neuroblastoma
NCT07437963 · National Cancer Institute (NCI)
2027-06-25 – 2029-09-30 · Recurrent Ganglioneuroblastoma, Recurrent Neuroblastoma, Refractory Ganglioneuroblastoma, Refractory Neuroblastoma
What this study did
NCT04211675 · Nationwide Children's Hospital
2022-09-01 – 2027-12 · Relapsed Neuroblastoma, Refractory Neuroblastoma
What this study did
NCT04238819 · Eli Lilly and Company
2020-11-09 – 2025-08-19 · Relapsed Solid Tumor, Refractory Solid Tumor
What this study did
NCT01592045 · United Therapeutics
2012-08 – 2014-06 · Neuroblastoma
What this study did
Phase 1 (5)
Neuroblastoma
NCT01711554 · National Cancer Institute (NCI)
2013-02-04 – 2027-03-03 · Recurrent Neuroblastoma, Refractory Neuroblastoma
What this study did
NCT02573896 · New Approaches to Neuroblastoma Therapy Consortium
2019-01-14 – 2026-12 · Neuroblastoma
What this study did
NCT04751383 · National Cancer Institute (NCI)
2021-08-31 – 2024-09-30 · High Risk Neuroblastoma, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Refractory Neuroblastoma, Resectable Osteosarcoma
What this study did
NCT03332667 · New Approaches to Neuroblastoma Therapy Consortium
2018-09-12 – 2024-02-23 · Neuroblastoma
What this study did
NCT00005576 · National Cancer Institute (NCI)
2001-01 – 2002-03 · Disseminated Neuroblastoma, Recurrent Neuroblastoma, Regional Neuroblastoma
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 1 (1)
Neuroblastoma
NCT05400603 · Emory University
2023-11-06 – 2026-12 · Neuroblastoma, Refractory Neuroblastoma, Relapsed Neuroblastoma, Relapsed Osteosarcoma, Refractory Osteosarcoma
What this study did

Competitive landscape

No competitors sharing a mechanism or indication in the current universe.

Upcoming events

(9 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Dinutuximab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
Phase 1NeuroblastomaActive not recruiting
Est. primary completion 2026-12 · NCT02573896 · CT.gov ↗
What to watch
Phase 1/2NeuroblastomaActive not recruiting
Est. primary completion 2026-12 · NCT04211675 · CT.gov ↗
What to watch
2028 (2)
November 2028 (1)
Phase 2NeuroblastomaActive not recruiting
Est. primary completion 2028-11 · NCT05421897 · CT.gov ↗
What to watch
December 2028 (1)
Phase 2NeuroblastomaRecruiting
Est. primary completion 2028-12 · NCT06450041 · CT.gov ↗
What to watch
2029 (2)
September 2029 (1)
Phase 1/2NeuroblastomaRecruiting
Est. primary completion 2029-09-30 · NCT07437963 · CT.gov ↗
What to watch
December 2029 (1)
Phase 3NeuroblastomaRecruiting
Est. primary completion 2029-12-31 · NCT06172296 · CT.gov ↗
What to watch
2030 (2)
September 2030 (1)
Phase 3NeuroblastomaRecruiting
Est. primary completion 2030-09-30 · NCT03126916 · CT.gov ↗
What to watch
December 2030 (1)
Phase 2NeuroblastomaNot yet recruiting
Est. primary completion 2030-12-31 · NCT07261241 · CT.gov ↗
What to watch
2031 (1)
November 2031 (1)
Phase 2NeuroblastomaRecruiting
Est. primary completion 2031-11-26 · NCT07932808 · CT.gov ↗
What to watch

See the full readout calendar ↗